Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing aqueous outflow Demonstrates neuroprotection independent of IOP reduction Supports continued development of PL9588 as a novel, dual-action glaucoma therapyCRANBURY, N.J., May 5, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data fo ...